Protein delivery by subviral particles of human cytomegalovirus

Gene Therapy

Volumn 10, Issue 3, 2003, Pages 278-284

  Pepperl Klindworth, S ^a   Frankenberg, N ^a   Riegler, S ^b   Plachter, B ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cytomegalovirus; Dense bodies; Protein delivery

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEOMYCIN; PHOSPHOTRANSFERASE; POLYPEPTIDE; RECOMBINANT PROTEIN; VACCINE;

CONTROLLED STUDY; DENDRITIC CELL; DENSE BODY; DNA MODIFICATION; FIBROBLAST; GENE TECHNOLOGY; GENE THERAPY; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

CYTOMEGALOVIRUS; DENDRITIC CELLS; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; KANAMYCIN KINASE; LUMINESCENT PROTEINS; RECOMBINANT FUSION PROTEINS; SECRETORY VESICLES; VACCINES, DNA;

CYTOMEGALOVIRUS; DNA VIRUSES; HERPESVIRIDAE; HUMAN HERPESVIRUS 5;

EID: 0037319266     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301879     Document Type: Review

References (34)

1. Sigal LJ et al. Cytotoxic T-cell immunity to virus-infected nonhaematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398: 77-80.
2. Arrode G et al. Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells. J Virol 2000; 74: 10 018-10 024.
3. Irmiere A, Gibson W. Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology 1983; 130: 118-133.
4. Schmolke S et al. Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J Virol. 1995; 69: 1071-1078.
5. Pepperl S et al. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol. 2000; 74: 6132-6146.
6. Topilko A, Michelson S. Hyperimmediate entry of human cytomegalovirus virions and dense bodies into human fibroblasts. Res Virol 1994; 145: 75-82.
7. Wolff D, Jahn G, Plachter B. Generation and effective enrichment of selectable human cytomegalovirus mutants using site-directed insertion of the neo gene. Gene 1993; 130: 167-173.
8. Riegler S et al. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol 2000; 81: 393-399.
9. Pepperl-Klindworth S, Frankenberg N, Plachter B. Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles. J Clin Virol, in press.
10. Sherman LA et al. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 1992; 258: 815-818.
11. Vitiello A et al. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991; 173: 1007-1015.
12. Wills MR et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996; 70: 7569-7579.
13. Diamond DJ et al. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997; 90: 1751-1767.
14. Theodore L et al. Intraneuronal delivery of protein kinase C pseudosubstrate leads to growth cone collapse. J Neurosci 1995; 15: 7158-7167.
15. Derossi D et al. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996; 271: 18 188-18 193.
16. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16: 440-443.
17. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988; 55: 1179-1188.
18. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-1193.
19. Morris MC et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-1176.
20. Schwarze SR et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-1572.
21. Walev I et al. Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O. Proc Natl Acad Sci USA 2001; 98: 3185-3190.
22. Ford KG et al. Protein transduction: an alternative to genetic intervention? Gene Ther. 2001; 8: 1-4.
23. Morris MC et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-1176.
24. Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1974; 1: 1-5.
25. Neff BJ et al. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med 1979; 160: 32-37.
26. Starr SE et al. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis 1981; 143: 585-589.
27. Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 1986; 234: 179-186.
28. Pickart CM, Rose IA. Ubiquitin carboxyl-terminal hydrolase acts on ubiquitin carboxyl-terminal amides. J Biol Chem 1985; 260: 7903-7910.
29. Chee MS et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Topics Microbiol Immunol 1990; 154: 125-169.
30. Schmolke S et al. The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J Virol 1995; 69: 5959-5968.
31. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1118.
32. Holtappels R et al. Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J Virol 2000; 74: 11 495-11 503.
33. Jonuleit H et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135-3142.
34. Herr W et al. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci USA 1999; 96: 12 033-12 038.